Announcements

FDA’s Guidance on Decentralized Trials: A Roadmap for Sites

Event Description: Speakers: Hosted by Scott Stout, CEO, MedVector Rocio Salazar, Associate Director R&D Procurement, Study Procurement Partner Jonathan Helfgott, Johns Hopkins University, President Association of Graduate Regulatory Educators, Former FDA Senior Leader Chris Popple, CEO, Nexus Collaboration Partners Brad Hightower, CEO, Hightower Clinical Research Description How can sites effectively leverage new diversity-focused rules and…

Scott Stout: Decentralizing Clinical Trials and Rewiring Access to Innovation

CRPN Central LIVE! Diversity Inclusion-Have changes occurred? A follow up…

MedVector Founder and CEO On Decentralization in Clinical Research

Improving Your Access to Clinical Trials — And Why It Matters

Think of the biggest medical breakthroughs of the modern era. Anything you can name, from the end of smallpox to the recent development of COVID-19 vaccines, owes its existence to clinical research. Clinical research uncovers new or improved treatments for both rare and common conditions, and clinical trials confirm their efficacy and safety in humans.…

Scott Stout, MedVector

Play Scott Stout has been recognized as one of the top healthcare innovators of 2021. While working as a professional investor in high-finance, Scott identified a large gap in the clinical trial marketplace and seized the opportunity to build a team of healthcare, high tech, and venture capitalists to turn his concept of expanding clinical…

CNS Summit Poster

Craig Lipset, Decentralized Clinical Trial Pioneer and Industry Innovator, Named as MedVector Board Member and Executive Advisor

LOS ANGELES…June 17, 2021 — Craig Lipset, a clinical trials industry innovator and leader, has joined the MedVector team as a new board member and executive advisor. MedVector’s novel Prime-Control Technology platform unlocks access to millions of potential clinical trial participants who are seen every day by physicians who are not seeking to become study…

MedVector Unveils Prime-Control Technology to Expand Subject Enrollment in Clinical Trials

MedVector introduces its Prime-Controltm Technology to provide contract research organizations and pharmaceutical sponsors with access to subjects for new clinical trials.  FREMONT, CA: MedVector has begun a nationwide rollout of its Prime-Controltm Technology, which will provide contract research organizations (CROs) and pharmaceutical sponsors with access to numerous patients without the requirement of new clinical trial sites.…

MedVector Launches its Prime-Control Technology to Expand Subject Enrollment Beyond Clinical Trial Sites

March 25, 2021 – MedVector has begun the rollout of its Prime-Controltm Technology, to give contract research organizations (CROs) and pharma sponsors access to patients without triggering new clinical trial sites. MedVector is the only company that partners with CROs, sponsors, and patient recruitment companies to expand subject participation beyond existing clinical trial sites. Clinical…

Scott Stout: Driven to Expand Clinical Trials Beyond Trial Sites

Scott Stout is driven by the desire to compete ─ either racing downhill mountain bikes, riding motorcycles, or growing a business. If there’s someone quicker, smarter or more experienced, so much the better for the agile and entrepreneurial Stout, who loves to compete and win, but doesn’t always have to be “the best.” In fact,…

MedVector Names John Neal, Chairman of PCRS Network, as Strategic Advisor, Pharma Relations and Clinical Protocol

LOS ANGELES…April 14, 2021 – MedVector announces that it has appointed John Neal, founder and chairman of PCRS Network, as strategic advisor, pharma relations and clinical protocol. MedVector partners with clinical research organizations (CROs), sponsors, and patient recruitment companies to expand subject participation beyond existing clinical trial sites, and reach diverse populations to fill and complete studies…